Drawing for ALZON

USPTO serial 79352129

ALZON

Reviewed by CopyMark Law Group

Reg. 7324464Status 700Registered
Filing date
Status date
Registration date
Mar 12, 2024
Examiner
LAM, HAI-LY HUYNH
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ALZON?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kisuk Lee

Kisuk Lee Harness, Dickey & Pierce, PLC7700 Bonhomme Avenue, Suite 400St. Louis, MO 63105UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic test reagents for medical or veterinary purposes; stem cells for medical purposes; diagnostic chemical reagents for medical use; antibodies for medical purposes; pharmaceutical preparations for the treatment of auto-immune diseases; autonomic drugs for medical purposes, namely, for the prevention and treatment of disorders of the nervous system; pharmaceutical preparations for the treatment of central nervous system (CNS) diseases; pharmaceutical preparations acting on the central nervous system; antispasmodics; radioactive pharmaceutical preparations for in vivo diagnostic use; pharmaceutical preparations and substances with analgesic properties; decoctions of medicinal herb; pharmaceutical preparations for the treatment of Parkinson's disease; vitamin and mineral dietary supplements; food supplements for medical purposes; nutraceutical preparations for therapeutic or medical purposes, namely, for promoting recognition function; biological tissue cultures for medical purposes; medical diagnostic test strips for blood analysis; vitamin supplement patchesACTIVE—
010Medical apparatus and instruments other than for dental purposes, namely, medical imaging apparatus; medical apparatus for the diagnosis of cerebrovascular diseases; medical apparatus for the diagnosis of neurological diseases; medical diagnostic apparatus for testing blood amyloid beta aggregates level; diagnostic apparatus for medical purposes, namely, for the detection of neurodegenerative disease; medical instrument for neurodegenerative diagnostics; immunoassay apparatus for medical diagnosis, namely, for diagnosing neurodegenerative diseases; testing probes for medical diagnostic purposes; blood testing apparatus; blood analysis equipment for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 11, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 19, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 19, 2024FIMPFINAL DISPOSITION PROCESSED—
Jun 13, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 12, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 12, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 26, 2023GPNXNOTIFICATION PROCESSED BY IB—
Dec 26, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 26, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 6, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 6, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 6, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 17, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 16, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 16, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 16, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 16, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 16, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 16, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 16, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Nov 16, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 7, 2023RFNTREFUSAL PROCESSED BY IB—
Jul 18, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 18, 2023RFRRREFUSAL PROCESSED BY MPU—
Jun 13, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 12, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 6, 2023DOCKASSIGNED TO EXAMINER—
Oct 18, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 14, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 13, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance